Below are the most recent publications written about "Immunotherapy, Adoptive" by people in Profiles.
-
Rejeski K, Sanz J, Fei T, Nair MS, Hashmi H, Avigdor A, Beyar-Katz O, B?cklein VL, Curran KJ, Einarsdottir S, Esensten JH, Glaubach N, Golan-Accav N, Gomez-Llobell M, Halamis I, Itzhaki O, Locke FL, Mailankody S, Marcus R, Maus MV, Palomba ML, Park JH, Pasquini M, Raj S, Rajeeve S, Salles G, Scordo M, Shah GL, Shimoni A, Subklewe M, Tix T, Usmani SZ, Valid O, Valtis YK, Zuckerman T, Shah NN, Perales MA, Shouval R. T-ICAHT: grading and prognostic impact of thrombocytopenia after CAR T-cell therapy. Blood. 2025 Aug 14; 146(7):834-846.
-
Gauthier J, Ahn KW, Patel J, Lian Q, Badawy S, Cairo MS, Delgado J, Grover N, Haverkos B, de Lima M, Malone A, Mussetti A, Nieto Y, Pawarode A, Pearson L, Solh M, Sureda A, Tun AM, Wudhikarn K, Yamshon S, Shadman M, Turtle CJ, Hamadani M, Herrera AF. CD19 CAR T-Cell Therapy for Primary Mediastinal Large B-Cell Lymphoma: A CIBMTR Analysis. Am J Hematol. 2025 Oct; 100(10):1792-1802.
-
Sidana S, Ahmed N, Akhtar OS, Brazauskas R, Oloyede T, Bye M, Hansen D, Ferreri C, Freeman CL, Afrough A, Anderson LD, Dhakal B, Dhanda D, Gowda L, Hashmi H, Harrison MJ, Kitali A, Landau H, Mirza AS, Patwardhan P, Qazilbash M, Usmani S, Patel K, Nishihori T, Ganguly S, Pasquini MC. Standard-of-care idecabtagene vicleucel for relapsed/refractory multiple myeloma. Blood. 2025 Jul 10; 146(2):167-177.
-
Einarsdottir S, Lobaugh S, Luan D, Gomez-Llobell M, Subramanian P, Devlin S, Chung D, Dahi PB, Falchi L, Giralt S, Landau H, Lesokhin AM, Lin R, Lue J, Mailankody S, Palomba ML, Park JH, Salles G, Scordo M, Escribano-Serrat S, Sanz J, Rejeski K, Shouval R, Usmani S, Perales MA, Shah G, Shahid Z. Humoral vaccine responses following Chimeric Antigen Receptor T-cell therapy for hematological malignancies. Blood Cancer J. 2025 Jul 02; 15(1):114.
-
Jagannath S, Martin TG, Lin Y, Cohen AD, Raje N, Htut M, Deol A, Agha M, Berdeja JG, Lesokhin AM, Liegel JJ, Rossi A, Lieberman-Cribbin A, Usmani SZ, Dhakal B, Parekh S, Li H, Wang F, Montes de Oca R, Plaks V, Sun H, Banerjee A, Schecter JM, Lendvai N, Madduri D, Lengil T, Zhu J, Koneru M, Akram M, Patel N, Costa Filho O, Jakubowiak AJ, Voorhees PM. Long-Term (=5-Year) Remission and Survival After Treatment With Ciltacabtagene Autoleucel in CARTITUDE-1 Patients With Relapsed/Refractory Multiple Myeloma. J Clin Oncol. 2025 Sep; 43(25):2766-2771.
-
Gerber WK, Xie Y, Patel SA. Expanding the Therapeutic Reach of Chimeric Antigen Receptor T-Cells and Bispecific T-Cell Engagers Across Solid Tumors. JCO Precis Oncol. 2025 Mar; 9:e2400753.
-
Kosti P, Abram-Saliba J, Pericou-Troquier L, Pavelot S, Ruggeri T, Laffaille M, Irving M, Coukos G, Lanitis E, Dunn SM. Potent and durable control of mesothelin-expressing tumors by a novel T cell-secreted bi-specific engager. J Immunother Cancer. 2025 Mar 13; 13(3).
-
Perica K, Jain N, Scordo M, Patel R, Eren OC, Patel U, Gundem G, Domenico D, Mitra S, Socci ND, Everett JK, Roche AM, Petrichenko A, Shah GL, Arcila ME, Borsu L, Park JH, Horwitz SM, Giralt SA, Dogan A, Leslie C, Papaemmanuil E, Bushman FD, Usmani SZ, Sadelain M, Mailankody S. CD4+ T-Cell Lymphoma Harboring a Chimeric Antigen Receptor Integration in TP53. N Engl J Med. 2025 Feb 06; 392(6):577-583.
-
Patel SA, Spiegel JY, Dahiya S. Second Primary Cancer After Chimeric Antigen Receptor-T-Cell Therapy: A Review. JAMA Oncol. 2025 Feb 01; 11(2):174-181.
-
Touzeau C, Krishnan AY, Moreau P, Perrot A, Usmani SZ, Manier S, Cavo M, Martinez Chamorro C, Nooka AK, Martin TG, Karlin L, Leleu X, Bahlis NJ, Besemer B, Pei L, Stein S, Wang Lin SX, Trancucci D, Verona RI, Girgis S, Miao X, Uhlar CM, Chastain K, Garfall AL. Efficacy and safety of teclistamab in patients with relapsed/refractory multiple myeloma after BCMA-targeting therapies. Blood. 2024 Dec 05; 144(23):2375-2388.